Page 70 - ENT 2026 e-program book final

TAKE CONTROL Rebuild

OF RECURRENT

NASAL POLYPS Live Allergy-Free

WITH NUCALA 1

THE ONLY ANTI-IL-5 APPROVED FOR NASAL
POLYPS 2

THE ONLY BIOLOGIC EXCLUSIVELY STUDIED
IN PATIENTS WITH ≥1 PREVIOUS NASAL
SURGERY 1,3-5
• Over 5X reduction in median nasal obstruction VAS
score vs. placebo (-0.82 vs -4.41, treatment difference
-3.14, 95% CI -4.09 to -2.18, adjusted p<0.0001)* . 1
• 69% reduction in need for surgery vs. placebo in
patients with ≥300 eosinophils/­L. 5
• 73% (n=150) of patients experienced improvement
in HRQoL. 1
sublingual immunotherapy
in Hong Kong for the treatment of allergic rhinitis and allergic asthma
the ONLY APPROVED

Acarizax is
®

HRQoL, health-related quality of life; VAS, visual analogue scale
SYNAPSE was a randomized, double-blind, placebo-controlled, parallel-group, multicenter phase 3 trials enrolling 407 adults with recurrent, refractory, severe, bilateral nasal polyp
symptoms assigned to receive either mepolizumab or placebo. The co-primary endpoints, change from baseline in total endoscopic nasal poly score at 52 week and mean nasal obstruction 1,2
1
VAS score during weeks 49-52, were met (p<0.0001 for both endpoints). Treatment-related AEs were reported in 15% and 9% of patients receiving mepolizumab and placebo, respectively. caused by house dust mite
Nucala (mepolizumab) for injection in pre-filled pen is indicated as an add-on therapy for adult patients with inadequately controlled hypereosinophilic syndrome (HES) without an
identifiable non-haematologic secondary cause. Nucala is also indicated as an add-on therapy for severe eosinophilic asthma (SEA), adults with severe CRSwNP for whom therapy
with systemic corticosteroids and/or surgery do not provide adequate disease control, and eosinophilic granulomatosis with polyangiitis (EGPA). 2 3
Important Safety Information • Nucala (mepolizumab) 100 mg solution for injection in pre-filled pen Contraindications: • Hypersensitivity to the active
2
substance or to any excipients of Nucala solution for injection. Warnings and Precautions: • Not to be used to treat acute asthma exacerbations.
Asthma-related adverse symptoms or exacerbations may occur during treatment. • Abrupt discontinuation of corticosteroids after initiation of Nucala Nasal and eye allergy symptoms are reduced by ~ 50% as early as 1 month
therapy is not recommended. • Acute and delayed systemic reactions, including hypersensitivity reactions (e.g. anaphylaxis, urticaria, angioedema, rash,
bronchospasm, hypotension), have occurred following administration of Nucala. • In the event of a hypersensitivity reaction, appropriate treatment as clinically
indicated should be initiated. • Pre-existing helminth infections should be treated before starting Nucala. • Nucala has not been studied in patients with organ
threatening or life-threatening manifestations of EGPA • Nucala has not been studied in patients with life-threatening manifestations of HES. Adverse Events:
Most commonly reported adverse reactions in: • Severe eosinophilic asthma: headache, injection site reactions and back pain. • CRSwNP: headache and
back pain. • EGPA: headache, injection site reactions and back pain • HES: headache, urinary tract infection, injection site reactions and pyrexia.
REFERENCES: 1. Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind,
placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(10):1141–1153. 2. Nucala (mepolizumab) 100mg solution for injection in pre-filled pen Hong Kong Full
Prescribing Information. Version HK112021 (GDS14/EMA20211112) 3. Bachert C, Han JK, Desrosiers MY, et al. Ežcacy and safety of benralizumab in chronic
rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial. J Allergy Clin Immunol. 2022;149(4):1309–1317.e12. 4. Gevaert P, Omachi TA, Corren J, et al.
Ežcacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595–605. 5. Bachert C, Han JK, Desrosiers
M, et al. Ežcacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results
from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394:1638–1650.
Please read the full The material is for the reference and use by Hong Kong healthcare professionals only. Unless noted, images and patient profiles are for illustrative purposes only.
prescribing information For adverse event reporting, please call GlaxoSmithKline Limited at (852) 3189 8989 (Hong Kong), or report via online Patient safety reporting form: For healthcare professionals only.
prior to administration. All content and images in this pamphlet are for reference purposes only.
Full prescribing https://gsk.public.reportum.com/. Trademarks are owned by or licensed to the GSK group of companies. References: 1. ACARIZAX ® Hong Kong prescribing information. 2. Drug Database. Pharmacy and Poisons Board of Hong Kong. Available at:
information is available ©2025 GSK group of companies or its licensor. https://www.drugoffice.gov.hk/eps/do/en/consumer/search_drug_database2.html. Accessed on 30 Jan 2026. 3. Sidenius K, et al. Pulm Ther. 2021;7(1):221-236.
upon request.
Abbott Laboratories Limited Redefine control in HDM allergies
GlaxoSmithKline Limited Suites 1004-10, 10/F, Tower 6, The Gateway, 9 Canton Road, Tsim Sha Tsui, Kowloon, Hong Kong Tel: (852) 3189 8989 20/F, AIA Tower, 183 Electric Road, North Point
Tel: (852) 2566 8711 Fax: (852) 2219 8001
PM-HK-MPL-ADVR-250001 (10/2027) Date of preparation: 11/2025